That trial will be the final confirmation that the helmet offers nothing so I do not see Novacure looking for a combo with DCVAX. The helmet device for GBM dies once DCVAX is approved. Why do you think they are desperately seeking alternative cancers. This will not help though because DCVAX is a true platform drug. No matter how you look at it, Novacure as a company will not survive once biologics take a hold in the cancer space. Again al IMHO.
News 
Market Data 
Discover 
